Search
Displaying 371–380 of 902 results for “vision connection”
-
Accessibility Statement & Guidelines
The Foundation Fighting Blindness is committed to providing communications that are accessible to the widest possible audience. With this goal in mind, our website is designed to Web Content Accessibility Guidelines (WCAG) 2.1 standards, an international standard that exceeds United States Federal Section accessibility 508 standards.
-
Preclinical and Translational Research Webinar Series
Odylia Therapeutics and the Foundation Fighting Blindness have teamed up to hold a four (4) part preclinical and translational research webinar series. This series will focus on genetic technologies for blinding diseases and will provide tangible advice and educational materials to researchers in the inherited retinal disease (IRD) space.
-
Researchers Identify Regions in the Retina to Target Therapies for Certain RP Patients
Research NewsUniversity of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Research NewsTreatment combines gene therapy and a device that generates and delivers retinal code
-
Jumping into an Uncharted Arena
Beacon StoriesThirty-one-year-old Wren Blae Zimmerman always loved horses. But it wasn’t until a few years ago that Wren finally learned to ride. Now her life revolves around this equestrian dream, and she’s given herself the title of the “Blind Show Jumper.”
-
Nacuity’s Emerging Anti-Oxidative Therapy Moves into Clinical Trial
Research NewsThe oral treatment shows promise for slowing vision loss in people with RP and Usher syndrome, regardless of genetic profile
-
Beacon Stories
Dr. Marciello doesn’t let a Stargardt disease diagnosis get in the way of his twin passions: medicine and baseball.
-
SparingVision Gets EU Funding Boost for Development of Cross-Cutting Gene Therapy
Research NewsA clinical trial for the treatment, designed to preserve cone photoreceptors, is planned in the US and Europe in 2020.
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
Research NewsIn a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
Foundation NewsMore than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
